Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin effects on appetite and weight regulation in type 2 diabetes
ISRCTN82062639Phase 4Completed
- Sponsor
- University of Leicester
- Start
- Sep 2016
- Modality
- Small Molecules
01
Overview
Phase 4, randomised, double-blind trial of empagliflozin in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by University of Leicester. Primary endpoint: Total peptide YY concentration at 24 weeks. Started Sep 2016; status: completed.
02
Drugs
empagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ISRCTN82062639.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN82062639.